Literature DB >> 28700786

Neoadjuvant Treatment in Locally Advanced and Borderline Resectable Pancreatic Cancer vs Primary Resectable Pancreatic Cancer.

Marco Del Chiaro1, Roberto Valente1,2, Urban Arnelo1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28700786     DOI： 10.1001/jamasurg.2017.2228

Source DB:  PubMed          Journal:  JAMA Surg        ISSN： 2168-6254            Impact factor:   14.766


× No keyword cloud information.
  3 in total

Review 1.  Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?

Authors:  Marco Vivarelli; Federico Mocchegiani; Daniele Nicolini; Andrea Vecchi; Grazia Conte; Enrico Dalla Bona; Roberta Rossi; Andrea Benedetti Cacciaguerra
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

Review 2.  Contemporary Management of Localized Resectable Pancreatic Cancer.

Authors:  Anuhya Kommalapati; Sri Harsha Tella; Gaurav Goyal; Wen Wee Ma; Amit Mahipal
Journal:  Cancers (Basel)       Date:  2018-01-20       Impact factor: 6.639

Review 3.  NF-κB Dependent Chemokine Signaling in Pancreatic Cancer.

Authors:  Claudia Geismann; Heiner Schäfer; Jan-Paul Gundlach; Charlotte Hauser; Jan-Hendrik Egberts; Günter Schneider; Alexander Arlt
Journal:  Cancers (Basel)       Date:  2019-09-26       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.